Momelotinib

Small molecule

Also known as GSK3070785

Approvedregulatory verdict

Evidence outlook

Approved: intermediate or high‑risk myelofibrosis (MF), including primary MF or secondary MF... (FDA)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

Also approved (1)
US
  • OJJAARA is indicated for the treatment of intermediate or high‑risk myelofibrosis (MF), including primary MF or secondary MF [post‑polycythemia vera (PV) and post‑essential thrombocythemia (ET)], in adults with anemia.
Product first approved 2023FDA label

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Other / comorbidity
NCT01969838 · Sierra Oncology LLC - a GSK company
2013-12-06 – 2019-05-02 · Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
What this study did
NCT02101021 · Sierra Oncology LLC - a GSK company
2014-06-02 – 2017-04-10 · Metastatic Pancreatic Ductal Adenocarcinoma
What this study did
Phase 2 (3)
Myelodysplastic Syndromes
NCT06847867 · GlaxoSmithKline
2025-06-05 – 2027-12-29 · Myelodysplastic Syndromes
What this study did
Other / comorbidity
NCT07098936 · Groupe Francophone des Myelodysplasies
2025-11-25 – 2028-11 · VEXAS Syndome, Myelo Dysplastic Syndrome
What this study did
NCT05980806 · Karyopharm Therapeutics Inc
2024-04-22 – 2028-10 · Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia
What this study did
Phase 1/2 (3)
Other / comorbidity
NCT04176198 · Sumitomo Pharma America, Inc.
2019-12-16 – 2030-04-30 · Myelofibrosis
What this study did
NCT06235801 · M.D. Anderson Cancer Center
2024-05-22 – 2029-10-01 · Myeloid Leukemia
What this study did
NCT07734077 · John Mascarenhas
2026-12-01 – 2028-12-01 · Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
What this study did
Phase 1 (2)
Myelodysplastic Syndromes
NCT07071155 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2026-03-19 – 2028-07-30 · Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Overlap Neoplasms, Chronic Neutrophilic Leukemia
What this study did
Other / comorbidity
NCT06150157 · Janssen Research & Development, LLC
2023-12-20 – 2028-06-14 · Neoplasms
What this study did
Phase 4 (1)
Other / comorbidity
NCT07498205 · SWOG Cancer Research Network
2026-11 – 2031-08-08 · Myelofibrosis, Myelofibrosis (MF)
What this study did

Competitive landscape

This drug's own stage for Myelodysplastic Syndromes: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Momelotinib: this drugPhase 2Small moleculeJAK1 / JAK2 / ACVR1not yet gradedNo reviewed efficacy summary in this indication
AzacitidineApprovedSmall moleculeDNMT1 (DNA methyltransferase 1)not yet gradedNo reviewed efficacy summary in this indication
Decitabine / Cedazuridine (Inqovi)ApprovedSmall moleculeDecitabine/cedazuridine fixed combination (DNMT + CDA inhibition)Partial signalFeatured results are non-efficacy only in this race
Imetelstat (Rytelo)ApprovedRNA / oligonucleotideTelomeraseReliable signalNo reviewed efficacy summary in this indication
LenalidomideApprovedSmall moleculeCereblon E3 ubiquitin-ligase, Thalidomide Analognot yet gradedNo reviewed efficacy summary in this indication
ElriterceptPhase 3UndisclosedActivin A/Bnot yet gradedNo reviewed efficacy summary in this indication
Roxadustat (Evrenzo)Phase 3Small moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)not yet gradedNo reviewed efficacy summary in this indication
AND017Phase 2Small moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)not yet gradedNo reviewed efficacy summary in this indication
R289Phase 1/2Small moleculeIRAK1/IRAK4not yet gradedNo reviewed efficacy summary in this indication
PF-08046040
—(overall)
UndisclosedCD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70not yet gradedNo reviewed efficacy summary in this indication
REGN17235
—(overall)
Multispecific antibodySLC3A2 x CD3not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(9 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Momelotinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (5)
April 2027 (1)
Phase 1/2MyelofibrosisRecruiting
Est. primary completion 2027-04-30 · NCT04176198 · CT.gov ↗
What to watch
June 2027 (2)
Phase 2Myelofibrosis, Moderate Thrombocytopenia, Mild ThrombocytopeniaRecruiting
Est. primary completion 2027-06 · NCT05980806 · CT.gov ↗
What to watch
Phase 1NeoplasmsRecruiting
Est. primary completion 2027-06-14 · NCT06150157 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Myelodysplastic SyndromesRecruiting
Est. primary completion 2027-07-14 · NCT06847867 · CT.gov ↗
What to watch
October 2027 (1)
Phase 1/2Myeloid LeukemiaRecruiting
Est. primary completion 2027-10-01 · NCT06235801 · CT.gov ↗
What to watch
2028 (3)
March 2028 (1)
Phase 1Myelodysplastic SyndromesRecruiting
Est. primary completion 2028-03-05 · NCT07071155 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2VEXAS Syndome, Myelo Dysplastic SyndromeRecruiting
Est. primary completion 2028-06 · NCT07098936 · CT.gov ↗
What to watch
December 2028 (1)
Phase 1/2Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia MyelofibrosisNot yet recruiting
Est. primary completion 2028-12-01 · NCT07734077 · CT.gov ↗
What to watch
2029 (1)
August 2029 (1)
Phase 4Myelofibrosis, Myelofibrosis (MF)Not yet recruiting
Est. primary completion 2029-08-08 · NCT07498205 · CT.gov ↗
What to watch

See the full readout calendar ↗